<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005981</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1298</org_study_id>
    <secondary_id>U01CA063200</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-1298</secondary_id>
    <secondary_id>NCI-89</secondary_id>
    <nct_id>NCT00005981</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase II Trial of O6Benzylguanine and BCNU in Patients With Colon and Rectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      patients who have metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate of patients with metastatic colorectal carcinoma treated&#xD;
           with O6-benzylguanine and carmustine.&#xD;
&#xD;
        -  Evaluate tumor tissue biochemical and immunohistochemical predictors of response in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Correlate carcinoembryonic antigen levels in the peripheral blood with response in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive O6-benzylguanine (BG) IV over 1 hour and carmustine IV over 1 hour&#xD;
      (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6&#xD;
      weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-36 patients will be accrued for this study within 1.7-3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.</measure>
    <time_frame>Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-benzylguanine</intervention_name>
    <description>Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic colorectal carcinoma&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 8 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.2 mg/dL&#xD;
&#xD;
          -  AST and ALT less than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT no greater than ULN (not on anticoagulation therapy)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatine clearance greater than 60 mL/min&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 60%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
&#xD;
          -  No other concurrent active malignancies&#xD;
&#xD;
          -  Prior malignancies presumed to be cured allowed&#xD;
&#xD;
          -  No other concurrent uncontrolled severe medical problem that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 6 months since prior adjuvant chemotherapy without disease recurrence&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior adjuvant radiotherapy allowed&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of total bone marrow&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior therapy for advanced disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Smitha Krishnamurthi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Smitha Krishnamurthi, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Cancer Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

